Author

Aleksandra Cios

University of Maryland, BaltimoreORCID 0000-0001-7702-4308Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metagenomics· 1

Frequent Co-Authors

Bolni Marius NagaloiD· 3 shared Chiswili Yves ChabuiD· 2 shared Elizabeth A. RaupachiD· 2 shared Khandoker Usran Ferdous· 2 shared Mitesh J. BoradiD· 2 shared Mulu Z. TesfayiD· 2 shared Natalie M. ElliottiD· 2 shared Omeed MoaveniD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Bolni Marius NagaloORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal for ImmunoTherapy of CancerPeer-reviewedMay 1, 2026

Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response

Mulu Z. Tesfay, Aleksandra Cios, Zetao Cheng…·Bolni Marius Nagalo

Oncolytic virus-based delivery of an alloantigen improves antitumor immunity and synergizes with immune checkpoint inhibitors in pancreatic cancer.

1 citation

mousespatial transcriptomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 28, 2026

CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function

Chiswili Yves Chabu, Robert A. Kazmierczak, M Hasani…·Bolni Marius Nagalo

This paper develops iSTORM, a Salmonella-based immunotherapy that silences CMTM6 in PDAC tumors, enhancing T-cell function and tumor control while maintaining safety.

DOI 10.64898/2026.01.26.701790

mouseproteomics

𝕏 PostBluesky

Molecular BiologybioRxivPreprintAug 1, 2025

Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment

Natalie M. Elliott, Benjamin Luke Kendall, Souyma Dutta…·Mitesh J. Borad

A glycoprotein-engineered vesiculovirus platform circumvents neutralizing antibodies, enabling repeat intravenous dosing and sustained anti-tumor immunity in preclinical models.

1 citation

mouseexperimental assay

𝕏 PostBluesky